The association of Pro12Ala polymorphism of peroxisome proliferator- activated receptor-γ gene with serum osteoprotegerin levels in healthy Korean women

Experimental and Molecular Medicine

Volumn 39, Issue 6, 2007, Pages 696-704

  Rhee, Eun Jung ^a   Oh, Ki Won ^a   Yun, Eun Joo ^b   Jung, Chan Hee ^a   Park, Cheol Young ^a   Lee, Won Young ^a   Oh, Eun Sook ^c   Baek, Ki Hyun ^d   Kang, Moo Il ^d   Park, Sung Woo ^a   Kim, Sun Woo ^a  

^a Sungkyunkwan University   (South Korea)

^b Hallym University   (South Korea)

^c Mizmedi Hospital   (South Korea)

^d The Catholic University of Korea   (South Korea)

Author keywords

Alkaline phosphatase; Bone and bones; Osteoprotegerin; Polymorphism, genetic; PPAR

Indexed keywords

ALANINE; ALKALINE PHOSPHATASE; OSTEOPROTEGERIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROLINE; TRANSCRIPTION FACTOR;

ADIPOCYTE; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLELE; ANTHROPOMETRY; ARTICLE; BONE; BONE DENSITY; BONE METABOLISM; BONE MINERAL; CALCIUM EXCRETION; CALCIUM URINE LEVEL; CELL DIFFERENTIATION; CONTROLLED STUDY; DNA EXTRACTION; DNA POLYMORPHISM; ENZYME LINKED IMMUNOSORBENT ASSAY; EXON; FEMALE; FEMUR NECK; GENE ACTIVATION; GENETIC LINKAGE; GENOTYPE; HAPLOTYPE; HEALTH PROMOTION; HEIGHT; HUMAN; HUMAN EXPERIMENT; KOREA; LUMBAR SPINE; MEASUREMENT; MULTIPLE REGRESSION; NORMAL HUMAN; PREDICTOR VARIABLE; PROTEIN BLOOD LEVEL; RECEPTOR GENE; STATISTICAL SIGNIFICANCE; WEIGHT;

EID: 38049121046     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2007.76     Document Type: Article

References (37)

1. Akune T, Ohba S, Kamekura S, Yamaguchi M, Chung UI, Kubota N, Terauchi Y, Harada Y, Azuma Y, Nakamura K, Kadowaki T, Kawaguchi H. PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 2004;113:846-55
2. Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 2005;146:1226-35
3. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, Lane CR, Schaffner SF, Bolk S, Brewer C, Tuomi T, Gaudet D, Hudson TJ, Daly M, Groop L, Lander ES. The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000;26:76-80
4. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-5
5. Cecil JE, Fischer B, Doney AS, Hetherington M, Watt P, Wrieden W, Bolton-Smith C, Palmer CN. The Pro12Ala and C-681G variants of the PPARG locus are associated with opposing growth phenotypes in young schoolchildren. Diabetologia 2005;48:1496-502
6. Chae GN, Kwak SJ. NF-kappaB is involved in the TNF-alpha induced inhibition of the differentiation of 3T3-L1 cells by reducing PPARgamma expression. Exp Mol Med 2003;35:431-7
7. Chan BY, Gartland A, Wilson PJM, Buckley KA, Dillon JP, Fraser WD, Gallagher JA. PPAR agonists modulate human osteoclast formation and activity in vitro. Bone 2007;40:149-59
8. Clement K, Hercberg S, Passinge B, Galan P, Varroud-Vial M, Shuldiner AR, Beamer BA, Charpentier G, Guy-Grand B, Froguel P, Vaisse C. The Pro115Gln and Pro12Ala PPARγ gene mutations in obesity and type 2 diabetes. Int J Obes Relat Metab Disord 2000;24:391-3
9. Desvergne B, Wahli W. Peroxisome proliferators-activated receptors: nuclear control of metabolism. Endocr Rev 1999;20:649-88
10. Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R, Najib J, Laville M, Fruchart JC, Deeb S, Vidal-Puig A, Flier J, Briggs MR, Staels B, Vidal H, Auwerx J. The organization, promoter analysis, and expression of the human PPARγ gene. J Biol Chem 1997;272:18779-89
11. Hara K, Okada T, Tobe K, Yasuda K, Mori Y, Kadowaki H, Hagura R, Akanuma Y, Kimura S, Ito C, Kadowaki T. The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes. Biochem Biophys Res Commun 2000;271:212-6
12. Jackson SM, Demer LL. Peroxisome proliferator-activated receptor activators modulate the osteoblastic maturation of MC3T3-E1 preosteoblasts. FEBS Letters 2000;471:119-24
13. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43
14. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 2000;405:421-4
15. Lazarenko OP, Rzonca SO, Suva LJ, Lecka-Czernik B. Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat. Bone 2006;38:74-84
16. Lecka-Czernik B, Gubrij I, Moerman EJ, Kajkenova O, Lipschitz DA, Manolagas SC, Jilka RL. Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2. J Cell Biochem 1999;74:357-71
17. Lecka-Czernik B, Moerman EJ, Grant DF, Lehmann JM, Manolagas SC, Jilka RL. Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 2002;143:2376-84
18. Mancini FP, Vaccaro O, Sabatino L, Tufano A, Rivellese AA, Riccardi G, Colantuoni V. Pro12Ala substitution in the peroxisome proliferator-activated receptor-γ2 is not associated with type 2 diabetes. Diabetes 1999;48:1466-8
19. Masud S, Ye S. Effect of the peroxisome proliferator activated receptor-gene Pro12Ala variant on body mass index: a meta-analysis. J Med Genet 2003;40:773-80
20. Mbalaviele G, Abu-Amer Y, Meng A, Jaiswal R, Beck S, Pittenger MF, Thiede MA, Marshak DR. Activation of peroxisome proliferator-activated receptor-gamma pathway inhibits osteoclast differentiation. J Biol Chem 2000;275:14388-93
21. Meirhaeghe A, Fajas L, Helbecque N, Cottel D, Auwerx J, Deeb SS, Amouyel P. Impact of the Peroxisome Proliferator Activated Receptor gamma2 Pro12Ala polymorphism on adiposity, lipids and non-insulin-dependent diabetes mellitus. Int J Obes Relat Metab Disord 2000;24:195-9
22. Meirhaeghe A, Fajas L, Gouilleux F, Cottel D, Helbecque N, Auwerx J, Amouyel P. A functional polymorphism in a STAT5B site of the human PPAR gamma 3 gene promoter affects height and lipid metabolism in a French population. Arterioscler Thromb Vasc Biol 2003;23:289-94
23. Nuttall ME, Patton AJ, Olivera DL, Nadeau DP, Gowen M. Human trabecular bone cells are able to express both osteoblastic and adipocytic phenotype: implications for osteopenic disorders. J Bone Miner Res 1998;13:371-82
24. Ogawa S, Urano T, Hosoi T, Miyao M, Hoshino S, Fujita M, Shiraki M, Orimo H, Ouchi Y, Inoue S. Association of Bone mineral density with a polymorphism of the peroxisome proliferator-activated receptor g gene: PPARγ expression in osteoblasts. Biochem Biophys Res Commun 1999;260:122-6
25. Okazaki R, Toriumi M, Fukumoto S, Miyamoto M, Fujita T, Tanaka K, Takeuchi Y. Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro. Endocrinology 1999;140:5060-5
26. Reid IR, Plank LD, Evans MC. Fat mass is an important determinant of whole body bone density in premenopausal women but not in men. J Clin Endocrinol Metab 1992;75:779-82
27. Rhee EJ, Oh KW, Lee WY, Kim SY, Oh ES, Baek KH, Kang MI, Kim SW . The effects of C161→T polymorphisms in exon 6 of peroxisome proliferator-activated receptor-gamma gene on bone mineral metabolism and serum osteoprotegerin levels in healthy middle-aged women. Am J Obstet Gynecol 2005;192:1087-93
28. Rhee EJ, Oh KW, Lee WY, Kim SY, Oh ES, Baek KH, Kang MI, Kim SW. Effects of two common polymorphisms of peroxisome proliferator-activated receptor-gamma gene on metabolic syndrome. Arch Med Res 2006;37:86-94
29. Ringel J, Engeli S, Distler A, Sharma AM. Pro12Ala missense mutation of the peroxisome proliferator activated receptor g and diabetes mellitus. Biochem Biophys Res Commun 1999;254:450-3
30. Rosen ED, Spiegelman BM. PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 2001;276:37731-4
31. Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 2004;145:401-6
32. Schwartz AV, Sellmeyer DE, Vittinghoff E, Palermo L, Lecka-Czernik B, Feingold KR, Strotmeyer ES, Resnick HE, Carbone L, Beamer BA, Park SW, Lane NE, Harris TB, Cummings SR. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006;91:3349-54
33. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19
34. Sorocéanu MA, Miao D, Bai XY, Su H, Goltzman D, Karaplis AC. Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol 2004;183:203-16
35. Thomas T, Gori F, Khosla S, Jensen MD, Burguera B, Riggs BL. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology 1999;140:1630-8
36. Woo KM, Choi Y, Ko SH, Ko JS, Oh KO, Kim KK. Osteoprotegerin is present on the membrane of osteoclasts isolated from mouse long bones. Exp Mol Med 2002;34:347-52
37. Yasuda H, Shima N, Nakagawa N, Mochizucki SI, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Kanno T, Murakami A, Tsuda E, Morinaga T, Higashio K. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998;39:1329-37